---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-24-031881"
form_type: "8-K"
ticker: "PRPH"
cik: "0000868278"
company_name: "ProPhase Labs, Inc."
filed_at: "2024-08-14T23:59:59+00:00"
generated_at: "2026-05-31T09:32:13.511413+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# ProPhase Labs Q2 revenue falls 81% to $2.5M; net loss $(0.33) per share; eyes H2 growth

## Summary
- Net revenue $2.5M vs $13.2M YoY; net loss $6.2M ($0.33 per share) vs $3.4M ($0.20) in Q2 2023.
- COVID-19 testing revenue zero (126K tests in prior year); overall gross margin negative 19.2%.
- Pharmaloz projects $14-16M revenue and >$5M pre-tax profit over next 12 months; exploring potential sale.
- Nebula Genomics launching revamped DTC product 'DNA Complete' with influencer marketing campaign.
- Cash and equivalents $2.4M; working capital $16.1M; expects significant sequential revenue growth in Q3 2024.

## SEC filing metadata
- accession: 0001493152-24-031881
- form_type: 8-K
- ticker: PRPH
- cik: 0000868278
- company_name: ProPhase Labs, Inc.
- filed_at: 2024-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/868278/000149315224031881/0001493152-24-031881-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/868278/000149315224031881/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-24-031881
- JSON: https://secwatch.observer/filing/0001493152-24-031881.json
- Plain text: https://secwatch.observer/filing/0001493152-24-031881.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.